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Abstract
Background: Trimethylaminuria, or fish odor syndrome, includes a transient or mild malodor
caused by an excessive amount of malodorous trimethylamine as a result of body secretions.
Herein, we describe data to support the proposal that menses can be an additional factor causing
transient trimethylaminuria in self-reported subjects suffering from malodor and even in healthy
women harboring functionally active flavin-containing monooxygenase 3 (FMO3).
Methods: FMO3 metabolic capacity (conversion of trimethylamine to trimethylamine N-oxide)
was defined as the urinary ratio of trimethylamine N-oxide to total trimethylamine.
Results: Self-reported Case (A) that was homozygous for inactive Arg500stop FMO3, showed
decreased metabolic capacity of FMO3 (i.e., ~10% the unaffected metabolic capacity) during 120
days of observation. For Case (B) that was homozygous for common [Glu158Lys; Glu308Gly]
FMO3 polymorphisms, metabolic capacity of FMO3 was almost ~90%, except for a few days
surrounding menstruation showing < 40% metabolic capacity. In comparison, three healthy control
subjects that harbored heterozygous polymorphisms for [Glu158Lys; Glu308Gly] FMO3  or
homozygous for wild FMO3 showed normal (> 90%) metabolic capacity, however, on days around
menstruation the FMO3 metabolic capacity was decreased to ~60–70%.
Conclusion:  Together, these results indicate that abnormal FMO3 capacity is caused by
menstruation particularly in the presence, in homozygous form, of mild genetic variants such as
[Glu158Lys; Glu308Gly] that cause a reduced FMO3 function.
Background
Trimethylaminuria, or fish odor syndrome, includes a
transient or mild malodor caused by an excessive amount
of malodorous trimethylamine as a result of body secre-
tions [1,2]. The causal factor of excessive free trimethyl-
amine is reduced enzyme capacity, or maybe substrate
overload. The decreased enzyme capacity to form non-
odorous trimethylamine N-oxide could be a result by an
inherited deficiency (primary genetic trimethylaminuria)
and/or by hormonal modulation or liver damage (tran-
sient trimethylaminuria) [2,3]. For trimethylaminuria, at
least 40 genetic polymorphisms of the flavin-containing
monooxygenase 3 (FMO3) gene have been reported [4,5].
For transient trimethylaminuria, a change of metabolic
capacity in one individual around the time of menstrua-
tion has been reported [6]. Herein, we describe data to
support the proposal that menses can be an additional
factor causing transient trimethylaminuria in self-
reported subjects suffering from malodor and even in
healthy women harboring functionally active FMO3.
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Methods
Japanese female volunteers included two subjects suffer-
ing self-reported malodor that responded to an Internet
article and three healthy laboratory members as controls,
ranging from 21 to 37 years of age [5,7]. Written consent
was obtained from the individuals for publication of
study. FMO3 metabolic capacity (conversion of trimethyl-
amine to trimethylamine N-oxide) was defined as the uri-
nary ratio of trimethylamine N-oxide to total
trimethylamine (% of trimethylamine N-oxide/[trimeth-
ylamine + trimethylamine N-oxide]) determined by GC
[7]. The FMO3 DNA sequence of genomic DNA prepared
from peripheral lymphocytes or buccal cells from the
study participants was also analyzed [3,5]. The study par-
Decreased metabolic capacity of FMO3 (), as indicated as percent free trimethylamine (TMA, ●) to total trimethylamine (❍)  excreted in the urine, in relation to menstruation Figure 1
Decreased metabolic capacity of FMO3 (), as indicated as percent free trimethylamine (TMA, ●) to total trimethylamine (❍) 
excreted in the urine, in relation to menstruation. Filled boxes indicate the period of menstruation. Total urinary trimethyl-
amine and free trimethylamine concentrations were calculated as mmol trimethylamine (TMA)/mol creatinine. Cases (A) and 
(B) were self-reported subjects suffering from malodour genotyped for homozygotic inactive Arg500stop FMO3 and homozy-
gotic common [Glu158Lys; Glu308Gly] FMO3, respectively. Cases (C) and (D and E) were control subjects genotyped as het-
erozygotic for [Glu158Lys; Glu308Gly] FMO3 and homozygotic for wild FMO3, respectively.
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ticipants collected their urine samples using a procedure
described previously [7]. The ethics committee of Showa
Pharmaceutical University approved this study.
Results and discussion
As shown in Figure 1, Case (A) that was homozygous for
inactive Arg500stop FMO3 [5], showed decreased meta-
bolic capacity of FMO3 (i.e., 13 ± 10 % (mean ± SD, n =
20) of the unaffected metabolic capacity) during 120 days
of observation. For Case (B) that was homozygous for
common [Glu158Lys; Glu308Gly] FMO3  polymor-
phisms [1-3], metabolic capacity of FMO3 was almost
~90%, except for a few days surrounding menstruation. In
comparison, healthy control Case (C) that harbored het-
erozygous polymorphisms for [Glu158Lys; Glu308Gly]
FMO3 showed > 90% metabolic capacity and this was
greater than the reported unaffected ratio [1,6,7]. How-
ever, for Case (C), on days around menstruation the
FMO3 metabolic capacity was decreased to ~60–70%.
Control Cases (D) and (E) that were homozygous for wild
FMO3  also showed normal FMO3 metabolic capacity
(i.e., ~> 90%), except for days around menstruation.
Together, these results indicate that abnormal FMO3
capacity is caused by menstruation particularly in the
presence, in homozygous form, of mild genetic variants
such as [Glu158Lys; Glu308Gly] that cause a reduced
FMO3 function. This would further suggest that sex hor-
mones play a role in the variable regulation of FMO3.
Induced FMO3 activity during pregnancy [8] has been
reported, in accordance with the present results.
Conclusion
Menses can be a factor causing transient trimethylaminu-
ria even in healthy women harboring active enzymes. The
present information could be useful in relieving the symp-
toms for transient and/or mild trimethylaminuria for
affected females during menstruation.
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